SCHEMBL256035

SCHEMBL256035

C#Cc1ccc(-c2ccc(OC)cc2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 2/20 0.49
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44
CLK4 Q9HAZ1 2/20 0.43
ACACB O00763 1/20 0.43
ESR2 Q92731 1/20 0.42
PDE2A O00408 1/20 0.42
DYRK1A Q13627 3/20 0.42
PLK4 O00444 1/20 0.41
AURKA O14965 1/20 0.41
DYRK3 O43781 1/20 0.41
MAP4K4 O95819 1/20 0.41
NTRK1 P04629 1/20 0.41
INSR P06213 1/20 0.41
CDK1 P06493 1/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
CDK2 P24941 1/20 0.41
MARK3 P27448 1/20 0.41
FLT4 P35916 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13527880 0.85 PDE2A (0.43) MCHR1CLK4ACACBPDE2AALDH1A1
SCHEMBL28990983 0.85 PDE2A (0.43) MCHR1CLK4ACACBPDE2AALDH1A1
SCHEMBL7277131 0.84 MCHR1 (0.50) MCHR1PDGFRBPDGFRACLK4ACACB
SCHEMBL22533036 0.82 GRM5 (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL29549206 0.82 GRM5 (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL256022 0.79 GRM5 (0.41) PDGFRBPDGFRAACACBMAP4K4KDR
SCHEMBL256019 0.79 RXFP1 (0.49) CLK4ACACBPDE2ARXFP1NPC1
SCHEMBL19385063 0.77 RAB9A (0.45) MAP4K4NPC1RAB9AALDH1A1
SCHEMBL17141754 0.77 PDE2A (0.58) PDE2ANPC1RAB9AALDH1A1
SCHEMBL256038 0.76 ACACB (0.39) PDGFRBPDGFRAACACBMAP4K4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611771-B1 SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-11-23 EP disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-8835472-B2 Compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-16 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-23 US disclosed
WO-2012028676-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214785-A1 New compounds, pharmaceutical compositions and uses thereof ABCG2, PGA5, PDE6G MCHR1 3770/4885PDGFRB 4239/4885PDGFRA 4194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.